Cargando…
Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
OBJECTIVE: Rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone, once every 3 weeks (R-CHOP21) is commonly used in non-Hodgkin’s lymphoma (NHL), but accompanied by Pneumocystis carinii pneumonia (PCP) as a fatal treatment complication. This study aims to estimate the specific eff...
Autores principales: | Huang, Xiaojia, Huang, Xiaoting, Lin, Shen, Luo, Shaohong, Dong, Liangliang, Lin, Dong, Huang, Yaping, Xie, Chen, Nian, Dongni, Xu, Xiongwei, Weng, Xiuhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069585/ https://www.ncbi.nlm.nih.gov/pubmed/36972963 http://dx.doi.org/10.1136/bmjopen-2022-068943 |
Ejemplares similares
-
Treatment and Prophylaxis of Pneumocystis carinii Pneumonia in AIDS Patients
por: Smith, Don, et al.
Publicado: (2012) -
The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
por: Lin, Shen, et al.
Publicado: (2023) -
"Neumonitis por pneumocystis carinii" /
por: Ascencio Cortés, Leticia
Publicado: (1996) -
Molecular epidemiology of Pneumocystis carinii pneumonia.
por: Beard, C B, et al.
Publicado: (1996) -
Neumonía por pneumocystis carinii en sida /
por: Zamitis Hernández, Marcos Gilberto
Publicado: (1993)